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Abstract
Introduction: Autoantibodies to RNA helicase A (RHA) were reported as a new serological marker of systemic
lupus erythematosus (SLE) associated with early stage of the disease. Anti-RHA and other autoantibodies in
Mexican SLE patients and their correlation with clinical and immunological features were examined.
Methods: Autoantibodies in sera from 62 Mexican SLE patients were tested by immunoprecipitation of
35S-labeled
K562 cell extract and enzyme-linked immunosorbent assay (anti-U1RNP/Sm, ribosomal P, b2GPI, and dsDNA). Anti-
RHA was screened based on the immunoprecipitation of the 140-kDa protein, the identity of which was verified by
Western blot using rabbit anti-RHA serum. Clinical and immunological characteristics of anti-RHA-positive patients
were analyzed.
Results: Anti-RHA was detected in 23% (14/62) of patients, a prevalence higher than that of anti-Sm (13%, 8/62).
Prevalence and levels of various autoantibodies were not clearly different between anti-RHA (+) vs. (-) cases,
although there was a trend of higher levels of anti-RHA antibodies in patients without anti-U1RNP/Sm (P = 0.07).
Both anti-RHA and -Sm were common in cases within one year of diagnosis; however, the prevalence and levels of
anti-RHA in patients years after diagnosis did not reduce dramatically, unlike a previous report in American
patients. This suggests that the high prevalence of anti-RHA in Mexican patients may be due to relatively stable
production of anti-RHA.
Conclusions: Anti-RHA was detected at high prevalence in Mexican SLE patients. Detection of anti-RHA in races in
which anti-Sm is not common should be clinically useful. Racial difference in the clinical significance of anti-RHA
should be clarified in future studies.
Introduction
Systemic autoimmune rheumatic diseases such as sys-
temic lupus erythematosus (SLE), scleroderma (systemic
sclerosis), and polymyositis/dermatomyositis are serolo-
gically characterized by the production of autoantibodies
to cellular constituents [1,2]. Although autoantibodies
target various proteins, protein complexes, protein-
nucleic acid complexes, and nucleic acids, selection of
the target antigens is not a random event; rather, there
can be a tight link between the specificity of autoantibo-
dies each patient produces and the diagnosis or certain
clinical symptoms. Some of the specificities are detected
almost exclusively in patients with certain clinical diag-
nosis and considered pathognomonic. Anti-Sm and dou-
ble-stranded DNA (dsDNA) antibodies are highly
specific for the diagnosis of SLE and are included in the
classification criteria [3]. While anti-dsDNA antibodies
are found in approximately 70% of patients with SLE,
their production fluctuates depending on the lupus
activity and treatment they receive. Production of anti-
Sm antibodies is generally considered more stable and is
found in approximately 15% of patients with SLE;
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in prevalence in Caucasians [4]. Anti-ribosomal P and
anti-PCNA (proliferating cell nuclear antigen) antibodies
found in approximately 10% and approximately 2% of
patients with SLE also are considered specific for SLE
[1]. We have recently reported that, in addition to these
classic markers, autoantibodies to RNA helicase A
(RHA, also known as DNA helicase II), a 3’-5’ dsDNA/
RNA helicase [5] that belongs to the DExH superfamily
of helicases, are a new serological marker of SLE [1,4].
In the previous report, the rates of prevalence of anti-
RHA were 6% (8/133) in Caucasians, 2.9% (3/103) in
African-Americans, and 12% (3/25) in the Latin popula-
tion in the US. Another earlier report was also from the
US [6]. Except for preliminary data suggesting that
approximately 10% of Japanese patients with SLE are
also positive [7], anti-RHA in other countries has not
been reported. Anti-RHA is also unique in that it is
associated with the early stage of the disease, typically
within a year of diagnosis of SLE. However, the number
in the Latin population was too small to analyze in the
previous study [4]. In the present study, we determined
t h ep r e v a l e n c eo fa n t i - R H A and examined the clinical
and immunological characteristics of anti-RHA-positive
Mexican patients with SLE.
Materials and methods
Patients
Sixty-two consecutive patients with SLE from the
Department of Rheumatology, Hospital General de
Occidente, Zapopan, Jalisco, Mexico, were studied. All
patients fulfilled the 1982 American College of Rheuma-
tology (ACR) SLE classification criteria [3]. Mex-SLE-
DAI (Mexican Systemic Lupus Erythematosus Disease
Activity Index) and Systemic Lupus International Colla-
borating Clinics/ACR Damage Indexes at the beginning
of the study were evaluated [8,9]. Complete blood
count, including lymphocyte count and serum rheuma-
toid factor (CELL-DYN 3500R; Abbott Diagnostics, Chi-
cago, IL, USA), was determined in all subjects.
Information on treatment of the day of sampling,
including use of immunosuppressive drugs (azathiopr-
ine, methotrexate, and cyclophosphamide), chloroquine,
and dose of steroid (milligrams of prednisone per day),
was recorded. The protocol was approved by the institu-
tional review board. This study meets and is in compli-
ance with all ethical standards in medicine, and written
informed consent was obtained from all patients accord-
ing to the Declaration of Helsinki.
Screening of autoantibodies in human sera by
immunoprecipitation
Immunoprecipitation (IP) using
35S-methionine-labeled
K562 cell extract to determine IgG class autoantibodies
was performed using 8 μL of sera as described [10]. Spe-
cificities such as anti-U1RNP, Sm, ribosomal P, Ro, La,
Ku, argonaute 2 (Ago2)/Su, and RNA polymerase II
(RNAP II) were verified using previously described
reference sera. Positive anti-U1RNP was defined based
on the presence of the set of U1RNP proteins (A, B’/B,
C, D1/D2/D3, E/F, and G). Since autoantibodies to
U5RNP without anti-Sm are very rare [11], IP of the
characteristic U5RNP 200-kDa proteins was used to
define anti-Sm (which immunoprecipitates U2, U4-6,
and U5 in addition to U1RNP) [10].
Anti-RHA was first screened based on IP of the 140-
kDa protein. Selected sera were then re-run on 8% SDS-
PAGE to verify that the mobility of the 140-kDa protein
was the same as that of RHA immunoprecipitated by the
r e f e r e n c es e r a .T h ei d e n t i t yo ft h e1 4 0 - k D ap r o t e i na s
RHA was further confirmed by IP-Western blot (WB) as
previously described [12]. Briefly, non-radiolabeled K562
cell extract from 5 × 10
6 cells was immunoprecipitated
with 2 μL of serum that immunoprecipitated the 140-
kDa protein in
35S-IP. Samples were run on 8% SDS-
PAGE and transferred to a nitrocellulose filter. The filter
was probed by rabbit anti-RHA antiserum (1:2,000, a gift
from Jun-Qi Yang and Michael B Mathews, University of
Medicine and Dentistry of New Jersey, Newark, NJ, USA)
[13] followed by 1:2,000 horseradish peroxidase-labeled
goat IgG F(ab’)2 anti-rabbit IgG (g-chain- and light-
chain-specific; SouthernBiotech, Birmingham, AL, USA)
and developed using SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce, Rockford, IL, USA).
Quantification of anti-RHA antibody levels
Levels of anti-RHA were estimated and analyzed using
the Storm Phosphorimager and images were obtained on
a storage phosphor screen (Amersham Biosciences, now
part of GE Healthcare, Little Chalfont, Buckinghamshire,
UK) from 8% SDS-PAGE gels. The integrated density
(that is, the sum of the values of the pixels in the image
or selection; this is equivalent to the product of the area
and the mean gray value) [14] of the RHA on a phos-
phorimage was calculated using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Enzyme-linked immunosorbent assay
Sera were tested for IgG anti-U1RNP/Sm, ribosomal
P( Pp e p t i d e ) ,d s D N A ,a n db2 glycoprotein I (b2GPI)
(a gift from Junichi Kaburaki, Tokyo Electric Power Com-
pany Hospital, Tokyo, Japan) antibodies by enzyme-linked
immunosorbent assay (ELISA) as described [15,16]. P pep-
tide was COOH-terminal 22 amino acids of human P0
protein [17]. dsDNA was purified using S1 nuclease as
described [15]. Anti-U1RNP/Sm antigen-capture ELISA
was performed as described [16]. Briefly, microtiter plates
(Immobilizer Amino™; Nalge Nunc, Rochester, NY, USA)
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(mAbs) 2.73 (IgG2a, anti-U1-70k) [10]. The left half of the
plate was incubated with K562 cell lysate (50 μL/well,
4×1 0
7/mL), and the right half was incubated with the
blocking buffer as control. After the plate was washed, an
identical set of samples and serially diluted standard
serum (1:500 to serial 1:5 dilutions) were added to the left
and right halves (control for reactivity against mouse IgG)
of the plate. Serum samples were tested at 1:500 and
1:2,500 dilutions, and data from the latter were used for
the analysis. Plates were washed with Tris-buffered saline/
Tween20, incubated with alkaline phosphatase-conjugated
mouse mAbs to human IgG (Sigma-Aldrich, St. Louis,
MO, USA) (1:1,000 dilution), and developed. The optical
density (OD) of 405 nm of wells was converted into units
based on the standard curve, and the units of the corre-
s p o n d i n gr i g h th a l f( w i t h o u tU 1 R N P / S ma n t i g e n s )w e r e
subtracted from the left half (with antigens) using SoftMax
Pro 4.3 software (Molecular Devices Corporation, Sunny-
vale, CA, USA) [15]. For the detection of anti-P peptide,
dsDNA, and b2GPI, microtiter plates were incubated with
1t o3μg/mL of the appropriate antigens, and ELISA was
performed as described previously using 1:500 diluted
sera. ODs were converted into units as described using the
appropriate standard [15].
Statistical analysis
All statistical analysis was performed using Prism 5.0 for
Macintosh (GraphPad Software, Inc., San Diego, CA,
USA). The Fisher exact test and the Mann-Whitney test
or Student t test were used to analyze prevalence and
levels, respectively, of autoantibodies and other data.
Results
A previous study suggested that anti-RHA was asso-
ciated with an early stage of SLE within a few years of
diagnosis [4]. Consistent with this observation, the levels
of anti-RHA dramatically decreased over time. Studies
in mouse models suggested that the environment for
the production of anti-RHA was distinct from that of
anti-small nuclear ribonucleoproteins (anti-snRNPs) or
anti-Su (Ago2) [12,18]. Opposite kinetics of production
of anti-RHA versus anti-snRNPs or anti-ribosomal P,
observed in some human cases, may be reminiscent of
these observations [4,7]. Thus, we examined whether
these findings in the previous human study performed
in an American (mainly Caucasian) population [4] also
apply to Mexican patients with SLE and whether anti-
RHA and anti-snRNPs have a negative correlation.
Screening of anti-RHA antibodies
Anti-RHA antibodies were screened based on the IP of
the 140-kDa protein using
35S-methionine-labeled K562
cell extract as described [4]. Sera selected were run
along with the prototype sera to verify the identical
mobility (Figure 1a). Several sera with strong reactivities
showing typical degradation patterns (white arrowheads,
see lanes RHA, 4, 5, 7, and 10) were clearly anti-RHA;
however, it is possible that there are other proteins that
co-migrate with RHA. Thus, IP-WB using rabbit anti-
RHA serum was also performed to verify the identity of
proteins immunoprecipitated by each serum (Figure 1b).
All 14 sera initially selected by IP were positive by IP-
WB, confirming that the sera indeed had anti-RHA.
Clinical and immunological characteristics of these
14 patients were compared with those of anti-RHA-
negative patients.
Prevalence of anti-RHA antibodies and stage of the
disease
Anti-RHA was found in 23% (14/62) in this cohort of
Mexican patients, a prevalence that was greater than
that of anti-Sm (13%) (Table 1) and much higher than
that of anti-RHA (6%) reported in American patients
[4], whereas the prevalence of other specificities did not
seem to be different from other reports in SLE.
The production of anti-RHA was associated with an
early stage of SLE in American patients [4]. To examine
whether this applies to Mexican patients, the prevalence
of anti-RHA was compared in groups classified based
on the years between diagnosis and screening test
(Table 2). Two of four patients within a year of diagno-
sis had anti-RHA; however, 9 out of 14 cases of anti-
RHA were after 5 years of diagnosis, suggesting that
anti-RHA does not disappear in Mexican patients with
SLE. This is in striking contrast to the Caucasian popu-
lation [7]. Also, the prevalence of anti-RHA was the
same as or higher than that of anti-Sm in patients even
more than 5 or 10 years after diagnosis. These results
were quite different from the pattern reported in the
previous American study [4]. Distributions of age at
diagnosis, age at anti-RHA test, and years between diag-
nosis and anti-RHA test were compared between anti-
RHA-positive (left in each panel) and -negative (right)
patients (Figure 2a, b, and 2c, respectively). All showed
no clear difference between anti-RHA (+) and (-)
groups.
Levels of anti-RHA antibodies and stage of the disease
and SLEDAI
Next, whether the levels of anti-RHA in patients years
after diagnosis are lower than those of patients with
early-disease status was evaluated by comparing the
intensity of RHA IP and years after diagnosis (Figure 2d).
Although the linear regression analysis suggested a nega-
tive association between these two, it was not statistically
significant. It appeared that the samples with very strong
anti-RHA antibodies and the ones with weak anti-RHA
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Page 3 of 9Figure 1 Analysis of autoantibodies to RNA helicase A (RHA). (a) Immunoprecipitation using anti-RHA-positive sera. Immunoprecipitation of
35S-methionine-labeled K562 cell extract by anti-RHA-positive sera from Mexican patients with systemic lupus erythematosus (SLE) (n = 14), anti-
RHA prototype serum (lane RHA), and a normal human serum (NHS) is shown. Number of years between initial diagnosis and anti-RHA test of
each patient is indicated below the lanes. Positions of RHA, UsnRNP components A, B’/B, U5-200k doublet, Ku (p70 and p80), Ro 60k, and
ribosomal P P0, and molecular weight (MW) are indicated. Positivity of anti-Sm and U1RNP is indicated at the top. White arrowheads indicate
major degradation products of RHA. (b) Immunoprecipitation and Western blot confirmation of anti-RHA. K562 cell extract was
immunoprecipitated by sera positive for the 140-kDa protein that co-migrated with RHA. Identity of the 140-kDa protein as RHA was validated
by Western blot using a rabbit anti-RHA serum. Lane RHA, anti-RHA prototype serum; lanes 1 to 6, anti-RHA-positive sera screened by
immunoprecipitation; lanes 7 to 9, NHS.
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disease, suggesting that anti-RHA levels do not decrease
dramatically, unlike in American patients in the previous
report [4].
Detailed information on SLE classification criteria was
available from 12 anti-RHA (+) and 42 anti-RHA (-)
patients. The prevalence of each SLE criteria was com-
pared between anti-RHA (+) and (-) groups to examine
whether anti-RHA (+) SLE had unique clinical features.
The prevalence of all criteria items appeared to be simi-
lar between groups (data not shown). Whether anti-
RHA (+) SLE had different disease activity was evaluated
by comparing SLEDAI between anti-RHA (+) and (-)
patients, but no clear difference was found (Figure 2e).
No correlation between the levels of anti-RHA antibo-
dies and disease activity was observed (Figure 2f).
Levels of various autoantibodies and anti-RHA antibodies
The prevalence of coexisting autoantibodies was not sig-
nificantly different betweena n t i - R H A - p o s i t i v ea n d
-negative patients (Table 1). Levels of anti-U1RNP/Sm,
-ribosomal P (P peptide), dsDNA, and b2GPI antibodies
by ELISA were compared between anti-RHA-positive
and -negative cases (Figure 3a-d); however, the differ-
ence was not apparent for any of these specificities.
The levels of anti-RHA quantified by phosphorimager
and those of anti-U1RNP/Sm by ELISA were compared.
Although the subjects with high levels of anti-RHA may
be more common in the anti-U1RNP/Sm-negative
group, the difference did not reach statistical signifi-
cance (P =0 . 0 7b yS t u d e n tt test) (Figure 3e). None of
the anti-U1RNP/Sm (+) cases (0/5) had an anti-RHA
integrated density of greater than 30,000 versus 56% (5/
9) in the anti-U1RNP/Sm (-) group (P = 0.086 by Fisher
exact test). There was a trend of negative correlation
between levels of anti-RHA and anti-U1RNP/Sm; how-
ever, it was not statistically significant (Figure 3f).
Discussion
Anti-Sm antibody is a well-established serological mar-
ker of SLE and is one of the minor criteria under immu-
nological disorders of the SLE classification criteria [3].
However, it is found in only approximately 15% of SLE
patients and in particular it is uncommon in Caucasians
[19]. Thus, an additional serological marker specific for
SLE should be clinically useful. Anti-RHA has recently
been reported as a new serological marker of SLE in the
US [4]. The rates of prevalence in the previous study
were 6% in the general SLE population, approximately
6% in Caucasians and African-Americans, and 12% in
the Latin population; however, only 3 out of 25 Latin
patients were positive. The present study showed a
much higher prevalence of anti-RHA: 23% in Mexican
patients with SLE. Although anti-RHA appears specific
for SLE in the previous study regardless of the race, the
number of Latin patients was relatively small [4]. Dis-
ease specificity of anti-RHA in other ethnicities, includ-
ing Mexicans, will need to be established in future
studies. In contrast to previous data [4], the presence of
anti-RHA was not skewed toward patients in an early
s t a g eo ft h ed i s e a s ei nt h ec u r r e n ts t u d y( T a b l e1 ) .A
comparison of years between diagnosis and anti-RHA
test versus levels of anti-RHA (Figure 2d) did not show
a clear negative correlation, suggesting a relatively stable
production of anti-RHA over time in Mexican patients.
There are several potential explanations for the discre-
p a n c y .O n ep o s s i b i l i t yi st h er a c i a ld i f f e r e n c e .T h ep r e -
vious study on anti-RHA-positive SLE included 8
Caucasians but only 3 African-Americans and 3 Latin
patients, indicating that the data were much affected by
the characteristics of Caucasian anti-RHA-positive SLE
patients. A recent analysis of the same study population
showed that the majority of Caucasian patients with
anti-RHA were at an early stage of SLE; 5 out of 8 anti-
RHA patients were within one year of diagnosis [7].
However, this may not be the case for other races, a cir-
cumstance that may potentially explain the difference.
A second difference is a distribution of different stages
of SLE patients for reasons that are not clear; the
Table 1 Frequency of autoantibodies in Mexican patients
with systemic lupus erythematosus
Total Anti-RHA (+) Anti-RHA (-)
Number of patients 62 14 48
RHA 23% (14/62)
U1RNP 29% (18/62) 36% (5/14) 27% (13/48)
Sm 13% (8/62) 21% (3/14) 10% (5/48)
Anti-Sm (+) among
anti-U1RNP (+)
44% (8/18) 60% (3/5) 38% (5/13)
Ribosomal P 8% (5/62) 14% (2/14) 6% (3/48)
Ro 39% (24/62) 29% (4/14) 42% (20/48)
La 8% (5/62) 0% (0/14) 10% (5/48)
Ku 6% (4/62) 14% (2/14) 4% (2/48)
Su 24% (15/62) 29% (4/14) 23% (11/48)
RNAP II 10% (6/62) 14% (2/14) 8% (4/48)
Not significant between anti-RHA (+) and (-) groups for all specificities by
Fisher exact test. RHA, RNA helicase A; RNAP II, RNA polymerase II.
Table 2 Frequency of anti-RHA and years from diagnosis
Years between
diagnosis and test
Number of
patients
Anti-RHA
(n = 14)
Anti-Sm
(n = 8)
0 to less than 1 4 50% (2/4) 75% (3/4)
1 to less than 2 5 0% (0/5) 0% (0/5)
2 to less than 5 15 20% (3/15) 0% (0/15)
5 to less than 10 17 12% (2/17) 12% (2/17)
10 or more 21 33% (7/21) 14% (3/21)
RHA, RNA helicase A.
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Page 5 of 9Figure 2 Age at diagnosis, age at anti-RNA helicase A (anti-RHA) test, and years between diagnosis and anti-RHA test.D e m o g r a p h i c
data of anti-RHA-positive (n = 14) and -negative (n = 48) systemic lupus erythematosus (SLE) patients were compared. (a) Age at diagnosis. (b)
Age at anti-RHA test. (c) Years from diagnosis to anti-RHA test. (d) Years from diagnosis to anti-RHA test versus levels of anti-RHA. (e) Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) in anti-RHA (+) versus (-) patients. (f) Correlation of SLEDAI and levels of anti-RHA. Anti-RHA
levels were measured as integrated density of RHA protein band using phosphorimager as described in Materials and methods. y, years.
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Page 6 of 9Figure 3 Levels of anti-RNA helicase A (anti-RHA) versus other autoantibodies. IgG anti-U1RNP/Sm, ribosomal P (P peptide), double-
stranded DNA (dsDNA), and b2 glycoprotein I (b2GPI) were determined by enzyme-linked immunosorbent assay. Serum dilutions used were
1:2,500 for anti-U1RNP/Sm and 1:500 for all others. Anti-RHA levels were semiquantified from immunoprecipitation using phosphorimager. (a)
Anti-U1RNP/Sm antibodies. (b) Anti-P peptide antibodies. (c) Anti-dsDNA. (d) Anti-b2GPI. (e) Anti-RHA levels in anti-U1RNP/Sm-positive versus
-negative sera. (f) Correlation of anti-RHA versus anti-U1RNP/Sm.
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patients in an early stage of SLE [4]. In the previous
study, the percentage of patients within 1 or 2 years
into the disease was nearly twice that of the present
study (13% versus 7%, 27% versus 15%, within 1 year
and 2 years, respectively). Although the reduction of
anti-RHA levels did not appear to be a simple result of
immunosuppressive therapy, current and historical treat-
ment may also have effects on the data mentioned
above. These points should be addressed in future stu-
dies with a large number of patients from different
ethnicities.
A hydrocarbon oil pristane induces autoantibodies to
snRNPs, ribosomal P, and Ago2/Su in normal mice
[20,21]; however, it inhibits the production of anti-RHA
antibodies in two strains of mice that spontaneously
produce anti-RHA: NZB/W F1 [12] and CBA/n
(x-linked immunodeficiency) [18]. In the former, pris-
tane induced anti-snRNP and anti-Ago2/Su antibodies
[12]. Human anti-RHA-positive cases that newly devel-
oped anti-snRNPs or -ribosomal P antibodies while their
anti-RHA levels drop significantly [4] appear to be remi-
niscent of the observations in animal models. Thus, it
seems reasonable to hypothesize that the environment
o rs t a g eo ft h ed i s e a s et h a ti sp r e f e r a b l ef o rt h ep r o d u c -
tion of anti-RHA is not ideal for the production of
other specificities. Although the difference was not sta-
tistically significant (P = 0.07, Student t test) (Figure 3e),
five cases with the highest levels of anti-RHA were in
the anti-snRNP-negative group. These may be the cases
that are going to ‘switch’ the specificities from anti-RHA
to anti-snRNPs later, like the previously described cases
[4]. Factors that are responsible for the production of
anti-RHA or switching from anti-RHA to anti-snRNPs
in humans are not known; however, in animal models of
pristane injection, which switches autoantibody specifi-
city from anti-RHA to anti-snRNP production, type I
interferon (I-IFN) [22,23] and Th1 cytokine shifting are
induced [12]. Thus, switching of autoantibody specifici-
ties in humans may also involve changes in cytokine bal-
ance, in particular Th1 cytokine or I-IFN production, or
Toll-like receptor (TLR) 7 stimulation since the produc-
tion of pristane-induced anti-snRNPs in animal models
is dependent on I-IFN [24] and TLR7 [25]. Environmen-
tal factors such as viral infection may trigger this type of
change via stimulation of TLRs or via a TLR-indepen-
dent mechanism of I-IFN induction [26]. Although the
production of lupus autoantibodies is generally consid-
ered an event prior to typical clinical manifestation [27],
it is of interest that 10% to 15% of autoantibodies
develop after the diagnosis, in particular within a year of
diagnosis [1]. The development of anti-snRNPs after
steroid treatment reported in clinically MCTD (mixed
connective tissue disease) patients [28,29] is interesting
when considering a role of treatment as a trigger to
change the environment of autoantibody production,
although differentiating the natural course from induc-
tion by steroids is virtually impossible. The identification
of mechanisms of induction and regulation of various
autoantibodies may help develop a strategy of therapeu-
tic regulation of autoantibody production.
Conclusions
T h ep r e s e n ts t u d yr e p o r t sah i g hp r e v a l e n c eo fa n t i -
RHA in Mexican patients with SLE. The detection of
SLE-specific autoantibodies in addition to anti-Sm
should be clinically helpful, in particular in the popula-
tion of patients with a low prevalence of anti-Sm.
Patients with high levels of anti-RHA appear to be more
common among anti-snRNP-negative patients. A strong
association of anti-RHA with an early stage of SLE was
not apparent in the Mexican population, possibly due to
the relatively stable production of anti-RHA over time.
Possible differences in clinical significance of anti-RHA
in different races should be clarified in future studies.
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